Shattuck Labs (NASDAQ:STTK) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a research report sent to investors on Friday, Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, HC Wainwright restated a buy rating and set a $28.00 target price on shares of Shattuck Labs in a research report on Thursday.

Shattuck Labs Trading Down 2.9 %

Shattuck Labs stock traded down $0.32 during mid-day trading on Friday, hitting $10.78. The stock had a trading volume of 255,663 shares, compared to its average volume of 294,183. The stock has a 50-day simple moving average of $9.42 and a two-hundred day simple moving average of $6.95. The stock has a market capitalization of $512.59 million, a PE ratio of -5.59 and a beta of 1.98. Shattuck Labs has a 12 month low of $1.33 and a 12 month high of $11.62.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.46%. The company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.30 million. Shattuck Labs’s revenue was up 2200.0% on a year-over-year basis. Sell-side analysts expect that Shattuck Labs will post -1.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, insider Stephen Stout sold 16,004 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total transaction of $168,522.12. Following the transaction, the insider now directly owns 74,437 shares in the company, valued at approximately $783,821.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.89% of the company’s stock.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently modified their holdings of STTK. Franklin Resources Inc. acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $11,663,000. Monashee Investment Management LLC acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $713,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 13.9% in the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after acquiring an additional 63,800 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $268,000. Finally, Reliant Investment Management LLC bought a new stake in Shattuck Labs during the 4th quarter worth approximately $143,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.